Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - A multicenter experience

Angelina Cistaro, Artor Niccoli Asabella, Pietro Coppolino, Natale Quartuccio, Corinna Altini, Mariapaola Cucinotta, Pierpaolo Alongi, Michele Balma, Silvia Sanfilippo, Ambra Buschiazzo, Arnoldo Piccardo, Margherita Fanelli, Gianmario Sambuceti, Jamshed Bomanji, Sergio Baldari, Gianni Bisi, Stefano Fanti, Giuseppe Rubini

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: To evaluate the diagnostic and prognostic role of fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in comparison to morphological imaging such as computed tomography in primary adrenal malignancies. Materials and Methods: In this multicenter retrospective study, 68 patients with adrenal malignancy were included. All patients had histologically proven diagnosis of primary adrenal malignancy (adrenocortical carcinoma, malignant pheochromocytoma, neuroblastoma and lymphoma), one whole body 18F-FDG PET/CT scan and one whole-body contrast enhancement computed tomography (CECT) scan acquired within one month and were followed clinically and by performing morphological tests for at least 12 months. Results: Overall sensitivity, specificity, accuracy, positive and negative predictive values for CECT and 18F-FDG PET/CT were respectively, 59%, 100%, 65%, 100%, 27% and 75%, 100%, 82%, 100% and 63%. For adrenocortical carcinomas, 18F-FDG PET/CT showed a better accuracy (93.4%) than CECT (75%). For neuroblastomas 18F-FDG PET/CT also showed better accuracy (70.4%) than CECT (66.7%). For malignant pheochromocytomas 18F-FDG PET/CT and CECT showed the same accuracy (90%). For primary adrenal lymphomas, 18F-FDG PET/CT showed better accuracy (100%) than CECT (74.41%). Kaplan-Mayer curves showed that "histotypes" and "metastases at the last follow-up" were similarly detected for both disease free survival (DFS) and overall survival (OS), while "global 18F-FDG PET/CT" and "presence of metastases at diagnosis" were significant for DFS. Stratifying the sample by the presence or absence of metastases at diagnosis, standardized uptake value (SUVmax) was a significant prognostic factor for DFS when metastases were absent (Wald test=7.035, P=0.008). Conclusion: Our multicenter study demonstrated that 18F-FDG PET/CT better than CECT diagnosed adrenal malignancies achieving also a good prognostic performance. Therefore management algorithms should include 18F-FDG PET/CT.

Original languageEnglish
Pages (from-to)97-102
Number of pages6
JournalHellenic Journal of Nuclear Medicine
Volume18
Issue number2
Publication statusPublished - Jun 1 2015

Fingerprint

Fluorodeoxyglucose F18
Adrenal Glands
Tomography
Neoplasms
Neoplasm Metastasis
Disease-Free Survival
Adrenocortical Carcinoma
Pheochromocytoma
Neuroblastoma
Multicenter Studies
Lymphoma
Fluorine
Deoxyglucose
Retrospective Studies
Sensitivity and Specificity
Survival

Keywords

  • Conventional imaging-prognosis
  • Malignancies-<sup>18</sup>F-FDG PET/CT
  • Primary adrenal gland

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Cistaro, A., Asabella, A. N., Coppolino, P., Quartuccio, N., Altini, C., Cucinotta, M., ... Rubini, G. (2015). Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - A multicenter experience. Hellenic Journal of Nuclear Medicine, 18(2), 97-102.

Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - A multicenter experience. / Cistaro, Angelina; Asabella, Artor Niccoli; Coppolino, Pietro; Quartuccio, Natale; Altini, Corinna; Cucinotta, Mariapaola; Alongi, Pierpaolo; Balma, Michele; Sanfilippo, Silvia; Buschiazzo, Ambra; Piccardo, Arnoldo; Fanelli, Margherita; Sambuceti, Gianmario; Bomanji, Jamshed; Baldari, Sergio; Bisi, Gianni; Fanti, Stefano; Rubini, Giuseppe.

In: Hellenic Journal of Nuclear Medicine, Vol. 18, No. 2, 01.06.2015, p. 97-102.

Research output: Contribution to journalArticle

Cistaro, A, Asabella, AN, Coppolino, P, Quartuccio, N, Altini, C, Cucinotta, M, Alongi, P, Balma, M, Sanfilippo, S, Buschiazzo, A, Piccardo, A, Fanelli, M, Sambuceti, G, Bomanji, J, Baldari, S, Bisi, G, Fanti, S & Rubini, G 2015, 'Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - A multicenter experience', Hellenic Journal of Nuclear Medicine, vol. 18, no. 2, pp. 97-102.
Cistaro, Angelina ; Asabella, Artor Niccoli ; Coppolino, Pietro ; Quartuccio, Natale ; Altini, Corinna ; Cucinotta, Mariapaola ; Alongi, Pierpaolo ; Balma, Michele ; Sanfilippo, Silvia ; Buschiazzo, Ambra ; Piccardo, Arnoldo ; Fanelli, Margherita ; Sambuceti, Gianmario ; Bomanji, Jamshed ; Baldari, Sergio ; Bisi, Gianni ; Fanti, Stefano ; Rubini, Giuseppe. / Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - A multicenter experience. In: Hellenic Journal of Nuclear Medicine. 2015 ; Vol. 18, No. 2. pp. 97-102.
@article{dbf1a6ef7213458d9c295505b341090d,
title = "Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - A multicenter experience",
abstract = "Objective: To evaluate the diagnostic and prognostic role of fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in comparison to morphological imaging such as computed tomography in primary adrenal malignancies. Materials and Methods: In this multicenter retrospective study, 68 patients with adrenal malignancy were included. All patients had histologically proven diagnosis of primary adrenal malignancy (adrenocortical carcinoma, malignant pheochromocytoma, neuroblastoma and lymphoma), one whole body 18F-FDG PET/CT scan and one whole-body contrast enhancement computed tomography (CECT) scan acquired within one month and were followed clinically and by performing morphological tests for at least 12 months. Results: Overall sensitivity, specificity, accuracy, positive and negative predictive values for CECT and 18F-FDG PET/CT were respectively, 59{\%}, 100{\%}, 65{\%}, 100{\%}, 27{\%} and 75{\%}, 100{\%}, 82{\%}, 100{\%} and 63{\%}. For adrenocortical carcinomas, 18F-FDG PET/CT showed a better accuracy (93.4{\%}) than CECT (75{\%}). For neuroblastomas 18F-FDG PET/CT also showed better accuracy (70.4{\%}) than CECT (66.7{\%}). For malignant pheochromocytomas 18F-FDG PET/CT and CECT showed the same accuracy (90{\%}). For primary adrenal lymphomas, 18F-FDG PET/CT showed better accuracy (100{\%}) than CECT (74.41{\%}). Kaplan-Mayer curves showed that {"}histotypes{"} and {"}metastases at the last follow-up{"} were similarly detected for both disease free survival (DFS) and overall survival (OS), while {"}global 18F-FDG PET/CT{"} and {"}presence of metastases at diagnosis{"} were significant for DFS. Stratifying the sample by the presence or absence of metastases at diagnosis, standardized uptake value (SUVmax) was a significant prognostic factor for DFS when metastases were absent (Wald test=7.035, P=0.008). Conclusion: Our multicenter study demonstrated that 18F-FDG PET/CT better than CECT diagnosed adrenal malignancies achieving also a good prognostic performance. Therefore management algorithms should include 18F-FDG PET/CT.",
keywords = "Conventional imaging-prognosis, Malignancies-<sup>18</sup>F-FDG PET/CT, Primary adrenal gland",
author = "Angelina Cistaro and Asabella, {Artor Niccoli} and Pietro Coppolino and Natale Quartuccio and Corinna Altini and Mariapaola Cucinotta and Pierpaolo Alongi and Michele Balma and Silvia Sanfilippo and Ambra Buschiazzo and Arnoldo Piccardo and Margherita Fanelli and Gianmario Sambuceti and Jamshed Bomanji and Sergio Baldari and Gianni Bisi and Stefano Fanti and Giuseppe Rubini",
year = "2015",
month = "6",
day = "1",
language = "English",
volume = "18",
pages = "97--102",
journal = "Hellenic Journal of Nuclear Medicine",
issn = "1790-5427",
publisher = "Hellenic Society of Nuclear Medicine",
number = "2",

}

TY - JOUR

T1 - Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - A multicenter experience

AU - Cistaro, Angelina

AU - Asabella, Artor Niccoli

AU - Coppolino, Pietro

AU - Quartuccio, Natale

AU - Altini, Corinna

AU - Cucinotta, Mariapaola

AU - Alongi, Pierpaolo

AU - Balma, Michele

AU - Sanfilippo, Silvia

AU - Buschiazzo, Ambra

AU - Piccardo, Arnoldo

AU - Fanelli, Margherita

AU - Sambuceti, Gianmario

AU - Bomanji, Jamshed

AU - Baldari, Sergio

AU - Bisi, Gianni

AU - Fanti, Stefano

AU - Rubini, Giuseppe

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Objective: To evaluate the diagnostic and prognostic role of fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in comparison to morphological imaging such as computed tomography in primary adrenal malignancies. Materials and Methods: In this multicenter retrospective study, 68 patients with adrenal malignancy were included. All patients had histologically proven diagnosis of primary adrenal malignancy (adrenocortical carcinoma, malignant pheochromocytoma, neuroblastoma and lymphoma), one whole body 18F-FDG PET/CT scan and one whole-body contrast enhancement computed tomography (CECT) scan acquired within one month and were followed clinically and by performing morphological tests for at least 12 months. Results: Overall sensitivity, specificity, accuracy, positive and negative predictive values for CECT and 18F-FDG PET/CT were respectively, 59%, 100%, 65%, 100%, 27% and 75%, 100%, 82%, 100% and 63%. For adrenocortical carcinomas, 18F-FDG PET/CT showed a better accuracy (93.4%) than CECT (75%). For neuroblastomas 18F-FDG PET/CT also showed better accuracy (70.4%) than CECT (66.7%). For malignant pheochromocytomas 18F-FDG PET/CT and CECT showed the same accuracy (90%). For primary adrenal lymphomas, 18F-FDG PET/CT showed better accuracy (100%) than CECT (74.41%). Kaplan-Mayer curves showed that "histotypes" and "metastases at the last follow-up" were similarly detected for both disease free survival (DFS) and overall survival (OS), while "global 18F-FDG PET/CT" and "presence of metastases at diagnosis" were significant for DFS. Stratifying the sample by the presence or absence of metastases at diagnosis, standardized uptake value (SUVmax) was a significant prognostic factor for DFS when metastases were absent (Wald test=7.035, P=0.008). Conclusion: Our multicenter study demonstrated that 18F-FDG PET/CT better than CECT diagnosed adrenal malignancies achieving also a good prognostic performance. Therefore management algorithms should include 18F-FDG PET/CT.

AB - Objective: To evaluate the diagnostic and prognostic role of fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in comparison to morphological imaging such as computed tomography in primary adrenal malignancies. Materials and Methods: In this multicenter retrospective study, 68 patients with adrenal malignancy were included. All patients had histologically proven diagnosis of primary adrenal malignancy (adrenocortical carcinoma, malignant pheochromocytoma, neuroblastoma and lymphoma), one whole body 18F-FDG PET/CT scan and one whole-body contrast enhancement computed tomography (CECT) scan acquired within one month and were followed clinically and by performing morphological tests for at least 12 months. Results: Overall sensitivity, specificity, accuracy, positive and negative predictive values for CECT and 18F-FDG PET/CT were respectively, 59%, 100%, 65%, 100%, 27% and 75%, 100%, 82%, 100% and 63%. For adrenocortical carcinomas, 18F-FDG PET/CT showed a better accuracy (93.4%) than CECT (75%). For neuroblastomas 18F-FDG PET/CT also showed better accuracy (70.4%) than CECT (66.7%). For malignant pheochromocytomas 18F-FDG PET/CT and CECT showed the same accuracy (90%). For primary adrenal lymphomas, 18F-FDG PET/CT showed better accuracy (100%) than CECT (74.41%). Kaplan-Mayer curves showed that "histotypes" and "metastases at the last follow-up" were similarly detected for both disease free survival (DFS) and overall survival (OS), while "global 18F-FDG PET/CT" and "presence of metastases at diagnosis" were significant for DFS. Stratifying the sample by the presence or absence of metastases at diagnosis, standardized uptake value (SUVmax) was a significant prognostic factor for DFS when metastases were absent (Wald test=7.035, P=0.008). Conclusion: Our multicenter study demonstrated that 18F-FDG PET/CT better than CECT diagnosed adrenal malignancies achieving also a good prognostic performance. Therefore management algorithms should include 18F-FDG PET/CT.

KW - Conventional imaging-prognosis

KW - Malignancies-<sup>18</sup>F-FDG PET/CT

KW - Primary adrenal gland

UR - http://www.scopus.com/inward/record.url?scp=84939616138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939616138&partnerID=8YFLogxK

M3 - Article

C2 - 26187207

AN - SCOPUS:84939616138

VL - 18

SP - 97

EP - 102

JO - Hellenic Journal of Nuclear Medicine

JF - Hellenic Journal of Nuclear Medicine

SN - 1790-5427

IS - 2

ER -